This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Kumamoto University, Ltt Bio-Pharma Co., Ltd.. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2013
Title: The Innovative Contributions of Masami Ohtsuka
Introduction
Masami Ohtsuka is a notable inventor based in Kumamoto, Japan. She has made significant contributions to the field of pharmaceuticals, particularly through her innovative work on loxoprofen derivatives. Her research focuses on developing compounds that minimize side effects while maximizing therapeutic benefits.
Latest Patents
Ohtsuka holds a patent for a novel loxoprofen derivative and pharmaceutical preparation containing the same. This invention addresses the common side effects associated with traditional loxoprofen, such as gastrointestinal disorders. The derivative exhibits excellent anti-inflammatory and analgesic effects, represented by specific chemical formulas. The halogen atoms in the compound can include chlorine, bromine, fluorine, or iodine, while the substituted phenyl group can feature various functional groups, enhancing its pharmacological properties.
Career Highlights
Throughout her career, Ohtsuka has worked with reputable organizations, including LTT Bio-pharma Co., Ltd. and Kumamoto University. Her experience in these institutions has allowed her to advance her research and contribute to the development of effective pharmaceutical solutions.
Collaborations
Ohtsuka has collaborated with esteemed colleagues such as Toru Mizushima and Yoshinari Okamoto. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Masami Ohtsuka's work exemplifies the impact of innovative thinking in the pharmaceutical industry. Her contributions, particularly in developing loxoprofen derivatives, highlight the importance of creating effective medications with minimal side effects.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile